Accelerate your path to the clinic with Aliri’s cost-effective, label-free whole-body PK service — designed to deliver deeper insights, faster decisions, and better outcomes for your drug candidates.

This approach enables tissue-level analysis, delivering insights into efficacy at the site of action, uncovering potential safety concerns, and supporting smarter clinical candidate selection.

Discover how this label-free whole-body QMSI combined with plasma LC-MS/MS can help identify the root causes of limited bioavailability and guide smarter optimization strategies early in development.

Explore how preserving spatial molecular information and leveraging AI-driven spatial-omics can transform treatment prediction, patient stratification, and personalized medicine.

According to the researchers, this plasma-based measurement has the potential to serve as a critical pharmacodynamic biomarker, facilitating the assessment of novel therapeutic approaches.

This innovative approach holds promise for reducing the need for extensive clinical drug-drug interaction studies, potentially streamlining the drug development process.

By leveraging this innovative combination, the assay achieves detection limits comparable to traditional methodologies while enhancing overall efficiency and reliability.

Our findings provide critical insights into refining ASO extraction protocols, which can enhance the accuracy of downstream analyses and support further research into ASO-based therapeutics.

Unlike conventional predictive biomarkers, which often focus on isolated molecular markers, this strategy integrates spatial metabolomics and genomics, providing a multidimensional perspective.

Hear how imaging mass cytometry, CyTOF, and single-cell sequencing unlock the secrets of the tumor microenvironment. Discover new insights into IL-18 and its impact on non-small cell lung cancer.

Our extensive portfolio includes a wide range of validated, off-the-shelf assays designed to support various research applications, ensuring flexibility and efficiency in your projects.

Utilizing statistical analysis and a proprietary metabolomics database, see how we detect and identify molecular toxicity markers, providing critical safety insights into potential drug candidates.

As OGNT-based therapeutics continue to gain traction in drug development, precise identification and quantification are essential for ensuring their efficacy and safety.

By leveraging this approach, researchers can streamline workflows, reduce costs, and enhance the efficiency of their bioanalytical processes.

Our longstanding relationships with regulatory agencies ensure that we provide high-quality, compliant bioanalytical solutions that meet the rigorous standards necessary for drug approval.

With decades of experience in molecular assay development for biomarker and PK/PD studies, our scientific team collaborates closely with sponsors to design tailored solutions.